Has Asiminib been included in China's medical insurance? What are the reimbursement conditions and proportions?

Aximini is a new drug specially used to treat chronic myelogenous leukemia (CML). However, the drug has not yet been officially launched in the Chinese market, so it is not included in the national medical insurance drug catalog. This means that patients cannot be reimbursed through medical insurance when receiving this drug treatment, which puts financial pressure on many patients and increases their treatment burden.

For patients facing high treatment costs, a viable alternative is a generic version of the drug called LuciAsc produced by Laos' Lucius Pharmaceuticals. This generic drug offers a more favorable price than the original drug, helping patients reduce their financial burden. Currently, each box of the Laos Lucius version of Assimini is 40mg*60 tablets and sells for about more than 4,000 yuan. Although the price may change due to exchange rate fluctuations and other factors, overall, LuciAsc is a cost-effective choice.

When purchasing the Laos Lucius version of Assimini, patients need to pay special attention to choosing formal channels to ensure the quality and safety of the purchased drugs. Patients are advised to seek help from qualified overseas medical institutions, which can not only provide accurate information but also ensure that the source of the medicine is reliable. After completing the purchase, patients should carefully check whether the outer packaging of the medicine is complete and confirm that the product information is consistent with that at the time of purchase. In addition, you should scan the anti-counterfeiting labels to verify the authenticity of the medicines to maintain your own medication safety.

In general, because Assimini has not yet been launched in the country, patients are temporarily unable to enjoy the medical insurance reimbursement policy. However, the generic drug LuciAsc launched by Laos Lucius Pharmaceutical Company provides patients with an optional treatment option. The key to this is that patients must choose formal channels to purchase drugs to ensure their quality and safety. At the same time, patients are advised to consult a professional doctor before using any medication to ensure the suitability of the treatment plan.

References:

https://www.drugs.com/history/scemblix.html